NCT01525784

Brief Summary

The incidence of Type 1 Diabetes Mellitus is increasing annually, in all pediatric age groups, especially among infants and toddlers.However, only 30% of diabetic children manage to achieve and maintain glycated hemoglobin A1c (HbA1c) levels below 8%, although most are treated by intensive insulin therapy.Recently, devices for real-time continuous glucose monitoring (RT-CGMS) have been introduced to aid self management of glycemic control. These devices enable the patients to see the interstitial glucose levels continuously, the trends of decrement and increment, and to have alarms prior to a severe hypoglycemic episode . The RT-CGMS was approved in Israel for routine usage in the pediatric population, 0-18 years in 2011, indicated for those with recurrent hypoglycemic episodes. So, the aim of the investigators study is to examine prospectively the short and long term effect of the RT-CGMS routine usage, in daily routine life of the diabetic child.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2012

Typical duration for all trials

Geographic Reach
1 country

4 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 3, 2011

Completed
3 months until next milestone

Study Start

First participant enrolled

February 1, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 3, 2012

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2014

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2014

Completed
Last Updated

February 3, 2012

Status Verified

February 1, 2012

Enrollment Period

1.9 years

First QC Date

November 3, 2011

Last Update Submit

February 1, 2012

Conditions

Keywords

rtCGMSglycemic controltype 1 diabetes mellitusyouth

Outcome Measures

Primary Outcomes (1)

  • to examine prospectively frequency of hypoglycemia

    3 years

Secondary Outcomes (2)

  • to assess the effect of rt-cgms on quality of life of children and parents

    3 years

  • To examine prosectively the effect of rt-cgms on glycemic control

    3 years

Study Arms (2)

Rt-CGMS

Using Rt-CGMS, approved by ministry of health as part f clinical care

Control

Not approved or suggested for RtCGMS. Other acceptabl means of therapy

Eligibility Criteria

Age1 Year - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodProbability Sample
Study Population

All patients recieving CGMS for treatment group and those without RTCGMS but all other management, for control group.

You may qualify if:

  • Age 1-18 years
  • Type 1 Diabetes Mellitus

You may not qualify if:

  • Refusal to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Soroka University Medical Center

Beersheba, Israel

Location

Wolfson Medical Center

Holon, Israel

Location

Sheba Medical Center

Tel Aviv, Israel

Location

Assaf harofeh Medical Center

Ẕerifin, 70300, Israel

Location

Related Publications (1)

  • Rachmiel M, Landau Z, Boaz M, Mazor Aronovitch K, Loewenthal N, Ben-Ami M, Levy-Shraga Y, Modan-Moses D, Haim A, Abiri S, Pinhas-Hamiel O. The use of continuous glucose monitoring systems in a pediatric population with type 1 diabetes mellitus in real-life settings: the AWeSoMe Study Group experience. Acta Diabetol. 2015 Apr;52(2):323-9. doi: 10.1007/s00592-014-0643-6. Epub 2014 Sep 16.

MeSH Terms

Conditions

HypoglycemiaDiabetes Mellitus, Type 1

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesDiabetes MellitusEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Marianna rachmiel, md

    Assaf Haroffeh Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Marianna Rachmiel, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr. Marianna Rachmiel, Assaf Haroffeh Medical Center

Study Record Dates

First Submitted

November 3, 2011

First Posted

February 3, 2012

Study Start

February 1, 2012

Primary Completion

January 1, 2014

Study Completion

June 1, 2014

Last Updated

February 3, 2012

Record last verified: 2012-02

Locations